Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03814616
Other study ID # SP-C-026-18
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date October 3, 2018
Est. completion date October 2019

Study information

Verified date September 2019
Source Shin Poong Pharmaceutical Co. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the efficacy of Pyramax administered for three-day, two-day or one day, in clearing a P. falciparum infection in asymptomatic carriers.

.


Description:

This is a randomized, open-label, three-arm, out-patient study in asymptomatic individuals with P. falciparum monoinfection confirmed at baseline, who are >5 years of age and >20kg body weight. A total of 300 participants will be randomised into the study; 100 participants in each of three treatment arms.

Patients who fulfil the entry criteria (all inclusion and none of the exclusion criteria) will be recruited and randomized to receive Pyramax orally for three days, two days or one day in a randomization ratio of 1:1:1.

All participants will be followed until Day 63 (counted from day 0) and blood samples will be taken on Days 0, 1, 2, 3, 7, 14, 21, 28, 35, 42 and 63 for malaria diagnostics, parasite density and qPCR. In addition, blood samples reverse-transcriptase (RT)-PCR will be taken on Days 0, 1, 2, 3, 7 and 14.

Participants will be administered local SOC treatment if they meet any of the protocol-specific criteria of treatment failure: Early treatment failure, Late clinical failure, or Late parasitological failure up to and including Day 63, or if the participant withdraws at any time before Day 63, and is parasite positive.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 300
Est. completion date October 2019
Est. primary completion date October 2019
Accepts healthy volunteers No
Gender All
Age group 5 Years and older
Eligibility Inclusion Criteria:

1. Evidence of asymptomatic infection with Plasmodium falciparum monoinfection on thin and thick blood smears with parasite density between 20/µL and 50,000/µL

2. Absence of any clinical symptoms of malaria at the time of enrolment and within 72 hours before enrolment

3. Age >5 years old and >20 kg body weight

4. Ability to swallow oral medication

5. Evidence of a personally signed and dated Informed Consent document indicating that the participant (or a legally acceptable representative if a participant is <18 years of age) has been informed of all pertinent aspects of the study and that all questions by the participant have been sufficiently answered. Assent will be obtained from participants <18 years of age as required by national regulations.

6. Participants who are willing to and are able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

1. Haemoglobin <7 g/dL (measured at screening)

2. History of having received any antimalarial treatment (alone or in combination) during the following periods before screening:

1. Piperaquine, mefloquine, naphthoquine or sulfadoxine-pyrimethamine within 6 weeks prior to screening

2. Amodiaquine, chloroquine within 4 weeks prior to screening

3. Any artemisinin derivative (artesunate, artemether or dihydroartemisinin), quinine, lumefantrine or any other anti-malarial treatment or antibiotic with antimalarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones and azithromycin) within 14 days prior to screening

3. Any herbal products or traditional medicines during the 7 days prior to screening (if spontaneously reported by the patient)

4. Known allergy to the study drugs (pyronaridine and/or any artemisinin derivatives)

5. Positive urinary pregnancy test for women of reproductive age

6. Lactating women

7. Evidence of severe malnutrition

8. Participation in other studies within 30 days before the current study begins and/or during study participation

9. Inability to comprehend and/or unwillingness to follow the study protocol

10. Previously randomized in this study

11. Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study. Examples would include but not limited to:

1. Immunological disorders (including known seropositive HIV antibody),

2. Severe psychiatric disorders (active depression, recent history of depression, generalised anxiety, psychosis, schizophrenia or other major psychiatric disorders) and major medical disorders related to cardiovascular, respiratory (including active tuberculosis), renal, gastrointestinal, endocrine, infectious, malignancy, neurological (including auditory) and history of convulsions or other abnormality (including recent head trauma),

3. Clinical signs or symptoms of hepatic injury (such as nausea, abdominal pain associated with jaundice) or known severe liver disease (i.e. decompensated cirrhosis, Child-Pugh stage 3 or 4)

12. Participant the Investigator considers at particular risk of receiving an anti-malarial or of participating in the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pyronaridine tetraphosphate 180mg:artesunate 60mg
ACT

Locations

Country Name City State
Gambia MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, Banjul,
Zambia Tropical Diseases Research Centre Ndola

Sponsors (2)

Lead Sponsor Collaborator
Shin Poong Pharmaceutical Co. Ltd. Medicines for Malaria Venture

Countries where clinical trial is conducted

Gambia,  Zambia, 

Outcome

Type Measure Description Time frame Safety issue
Other Parasite free by qPCR quantification To estimate the proportion of participants who are parasite free by qPCR quantification. 63 days
Other PCR-adjusted APR by qPCR To estimate PCR-adjusted APR by qPCR.To estimate PCR-unadjusted APR by qPCR. To estimate the rate of recurrent infections, recrudescences and new infections by qPCR until Day 63 (post first dose) by KM analysis. 63 days
Other Percentage change in gametocytaemia. In participants with positive detection of gametocytes by reverse transcriptase (RT)-PCR at baseline, to evaluate percentage reduction in gametocytaemia. 63 days
Other AUC of gametocytaemia by RT-PCR To estimate area under the curve (AUC) up to Day 14 of gametocytaemia by RT-PCR, in participants with positive RT-PCR at baseline and separately in participants with negative RT-PCR at baseline 14 days
Other Relationship between artesunate and pyronaridine concentration and efficacy To explore the relationship between artesunate and pyronaridine concentration and efficacy (PCR-adjusted APR at Day 28, based on slide assessment by microscopy) 28 days
Primary PCR-adjusted APR at Day 28 (based on slide assessment by microscopy) To assess the efficacy of each dosing regimen PCR-adjusted Adequate parasitological response (APR) at Day 28 Day 28
Secondary PCR-adjusted APR To assess the efficacy of each dosing regimen PCR-adjusted APR at Day 63 63 days
Secondary PCR-unadjusted APR To assess the efficacy of each dosing regimen PCR-unadjusted APR at Day 63 63 days
Secondary Rate of recurrent infections, recrudescence and new infections To assess the efficacy of each dosing regimen on rate of recurrent infections, recrudescence and new infections 63 days
Secondary Proportion of parasite free participants Proportion of participants who are parasite free by 4-8 hours, Day 1, Day 2 and Day 3 post first dosing 4 days
Secondary Gametocyte incidence The area under the curve (AUC) up to Day 14 (post first dose) of gametocytes in participants with gametocytes at baseline, and separately in participants without gametocytes at baseline 14 days
Secondary Adverse Events Number (%) of patients and number of events with:
TEAEs,
serious TEAEs,
study drug related TEAEs,
study drug related serious TEAEs,
malaria-related TEAEs,
malaria-related serious TEAEs
Number (%) of patients with TEAEs and drug-related TEAEs by maximum severity, based on Grade 1 to Grade 5 (CTCAE V4.03) severity grading Adverse events will be coded by MedDRA primary system organ class and preferred term.
Hepatotoxicity related TEAEs o The number and percentage of patients with hepatotoxicity related TEAEs, based on the Standard MedDRA Query (SMQ) narrow search "Drug-related hepatic disorders" will be summarised and clinical biochemistry parameters
63 days
Secondary Clinical laboratory data - Haematology Haemoglobin, haematocrit, erythrocytes, platelets, white blood cells, neutrophils, lymphocytes, monocytes, eosinophils, basophils will be summarised over time, as absolute values and changes from baseline with the number of observations, mean, standard deviation, median, quartiles, minimum and maximum. SI units will be used to summarise the data. 63 days
Secondary Clinical laboratory data - Biochemistry Total and conjugated bilirubin will be summarised over time, as absolute values and changes from baseline with the number of observations, mean, standard deviation, median, quartiles, minimum and maximum. SI units will be used to summarise the data. 63 days
Secondary Clinical laboratory data - Liver Enzymes Alanine aminotransaminase (ALT), Aspartate aminotransaminase (AST), Alkaline Phosphatase will be summarised over time, as absolute values and changes from baseline with the number of observations, mean, standard deviation, median, quartiles, minimum and maximum. IU/L units will be used to summarise the data 63 days
Secondary Clinical laboratory data - Liver Enzyme Elevations The number (%) of participants with liver enzyme elevations after first drug administration as defined below will be summarised.
ALT or AST > 3 x Upper Limit of Normal (ULN)
ALT or AST > 5 x ULN
ALT or AST > 8 x ULN
ALT or AST > 3 x ULN and bilirubin > 2 x ULN at the same time point (when conjugated bilirubin fraction is missing)
ALT or AST > 3 x ULN and bilirubin > 2 x ULN, together with a conjugated bilirubin fraction >35% (Potential Hy's law cases), at the same time point
63 days
Secondary Vital signs - Blood pressure Supine systolic and diastolic blood pressure (mm Hg) absolute values and changes from baseline will be summarised by time point with the number of observations, mean, standard deviation, median, minimum and maximum, and quartiles 63 days
Secondary Vital signs - Pulse rate Pulse rate (bpm) absolute values and changes from baseline will be summarised by time point with the number of observations, mean, standard deviation, median, minimum and maximum, and quartiles 63 days
Secondary Vital signs - Temperature Temperature (degrees Celsius) absolute values and changes from baseline will be summarised by time point with the number of observations, mean, standard deviation, median, minimum and maximum, and quartiles 63 days
See also
  Status Clinical Trial Phase
Terminated NCT04130282 - VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine Phase 1
Completed NCT04049916 - Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission Phase 2/Phase 3
Active, not recruiting NCT04079621 - Short Course Radical Cure of P. Vivax Malaria in Nepal Phase 4
Completed NCT05135273 - Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali Phase 1
Not yet recruiting NCT06083688 - Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi Phase 4
Recruiting NCT03511443 - Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections N/A
Completed NCT05550909 - Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali Phase 2
Recruiting NCT05306067 - Plasmodium Falciparum Genomic Intelligence in Mozambique
Completed NCT05081089 - Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali Phase 2
Recruiting NCT05150808 - Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania Phase 3
Recruiting NCT05757167 - Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics Phase 4
Completed NCT01992900 - A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria Phase 2
Completed NCT04565184 - Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde Phase 4
Completed NCT03896724 - Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso Phase 1/Phase 2
Completed NCT03454048 - Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 N/A
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Completed NCT03138096 - Safety and Protective Efficacy of Pb(PfCS@UIS4) Phase 1/Phase 2
Recruiting NCT04271306 - Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. Phase 1
Recruiting NCT05058885 - Plasmodium Vivax Among Duffy Negative Population in Cameroon.
Completed NCT04862416 - Safety and Efficacy of R0.6C Vaccine Phase 1